相关实验视频

Updated: Jul 8, 2025

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

来自Scoparia dulcis的一种新型拉巴丹二二,可以改善胰腺功能,通过Bax/Bcl-2/Caspase-3通路对胰岛细胞进行细胞亡

Lin Dong¹, Mimi Chen², Zibao Huang¹

¹Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Key Laboratory for Research and Development of Tropical Herbs, School of Pharmacy, Hainan Medical University, Haikou, 571199, China.

Journal of ethnopharmacology

|December 16, 2023

概括

斯科帕里亚杜尔西斯含有一种新的二维,斯科帕里科尔E,可以保护小岛细胞免受亡. 这种化合物调节了Bax/Bcl-2/Caspase-3通路,为糖尿病治疗提供了潜力.

科学领域:

植物化学植物化学
药理学药理学是指药理学的学科.
细胞生物学细胞生物学

背景情况:

斯科帕利亚杜尔西斯在治疗糖尿病方面具有民族药理学意义.
它的抗糖尿病特性与小岛保护有关,但机制尚不清楚.
来自S. dulcis的迪特尔类药物表现出降血糖和保护小岛的作用.

研究的目的:

为了研究来自S. dulcis.的新型二基斯科帕里科尔E.
在体外和体内检查其岛屿保护作用.
为了阐明潜在的作用机制.

主要方法:

使用光谱学方法阐明Scoparicol E的结构.
通过CCK-8试验评估细胞毒性和抗质活性.
在体内和体外的研究包括血清生物化学分析,西部涂抹和流动细胞计,以调查对岛屿损伤的保护机制.

主要成果:

在STZ诱导的糖尿病小鼠中,斯科帕里科尔E降低了高血糖.
它在体外和体外表现出显著的抗瘤作用.
斯科帕里科尔E抑制了Bax/Bcl-2/Caspase-3通路,阻止了细胞染色体c的释放,并恢复了MIN6细胞中的线粒体膜潜能.

结论:

这种新型的迪特尔化物斯科帕里科尔E保护小岛细胞免受亡.
这种保护是通过调节Bax/Bcl-2/Caspase-3信号通路来实现的.
斯科帕里科尔E为糖尿病相关的小岛细胞损伤提供了潜在的治疗剂.

关键词:

这是一种抗apoptotic的药物.巴克斯/Bcl-2/Caspase-3通路的使用小岛是一个小岛.这就是Scoparia dulciscis.斯科帕里科尔E E

更多相关视频

Improved Protocol For Laser Microdissection Of Human Pancreatic Islets From Surgical Specimens

Improved Protocol For Laser Microdissection Of Human Pancreatic Islets From Surgical Specimens

Published on: January 6, 2013

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...